Advanced Life Sciences, Cethromycin, Second Pivotal Phase III Trial for Treatment of Pneumonia

Nov. 15, 2007 - Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States... Advanced Life Sciences's Press Release -